Theravance Biopharma (TBPH) Tops Q1 EPS by 4c

Theravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($1.22), $0.04 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $6.43 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M